Sino Biopharm Reports Positive Phase III Results for Culmerciclib in Advanced Breast Cancer
I'm PortAI, I can summarize articles.
Sino Biopharmaceutical Limited reported positive interim results from its Phase III study (CULMINATE-2) of culmerciclib for HR+/HER2- advanced breast cancer. The study met its secondary endpoint, showing a median progression-free survival (PFS) not yet reached in the treatment group, compared to 22.0 months in the control group, indicating a 60% reduction in disease progression risk. The objective response rate was 59.3% in the treatment group versus 42.3% in the control group. Results were consistent across various subgroups, including those with poor prognosis.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments